Codis Announces Key Milestone Achievement in Haverhill Expansion
The demolition of Codis’ Haverhill site has been completed and the company has revealed it has started construction of a new commercial-scale spray-drying facility, with the expanded capacity due to enter service in late 2027.
Global CDMO that specializes in spray drying and amorphous solid dispersions (ASDs), Codis, has announced a key milestone in its PSD-4 expansion at its Haverhill site in Suffolk (1). The old facilities have now been fully demolished, paving the way for the construction of a new building that will accommodate a GEA Pharma-SD PSD-4 solvent-capable spray dryer.
The next phase of the project will work to increase Codis’ capacity for solvent-based spray drying, used to create ASDs to improve the solubility and bioavailability of poorly soluble drugs. By using existing site infrastructure, the company expects to deliver the additional capacity efficiently, with the dryer to be installed and validated before entering service in the final quarter of 2027. Progress on the expansion continues as planned, with the factory acceptance test for the dryer slated for November as the project’s next key milestone.
“Completing demolition and moving into construction is an important milestone for the PSD-4 expansion,” said Nick Hodgson, Vice-President and General Manager of Haverhill operations, in a company press release (1). “By building within our existing Haverhill facility and utilizing established site infrastructure, we can deliver the additional capacity efficiently while building on the expertise and capabilities already in place in our 100,000 sq ft CGMP facility.”
The Haverhill project forms part of a wider push by Codis to build an integrated UK manufacturing and development network. In August 2026, the company completed its acquisition of Catalent’s Nottingham facility, adding oral solid dose development and small-scale commercial manufacturing expertise to its European offering (2).
The Nottingham site is intended to complement Haverhill’s large-scale commercial spray-drying operation, together providing a route from early formulation development and analytical support through clinical supply and commercial-scale manufacturing.
Codis anticipates that the combined network will strengthen its ability to support customers moving promising poorly soluble molecules from development into commercial production. With construction under way at Haverhill and the Nottingham acquisition complete, the company is positioning its UK sites as the foundation of a global CDMO offering spanning development, scale-up and commercial supply.
References
1. Codis. Codis Completes Demolition and Begins Construction on PSD-4 Expansion at Haverhill. Press Release, Oct. 29, 2026.
2. The Pharma Navigator. Codis Expands European Footprint with Catalent Nottingham Facility Acquisition. thepharmanavigator.com, accessed Aug. 5, 2026.
